Document Classification

Section Type: RESULTS

Text: At day 42, last-observation-carried-forward endpoint, treatment with lurasidone was associated with significant improvement compared to placebo on the BPRSd (least squares mean + / - SE = -8. 9 + / - 1. 3 vs. -4. 2 + / - 1. 4 ; p =. 012), as well as on all secondary efficacy measures, including the PANSS total score (-14. 1 + / - 2. 1 vs. -5. 5 + / - 2. 2 ; p =. 004) and the PANSS positive (-4. 3 + / - 0. 7 vs. -1. 7 + / - 0. 7 ; p =. 006), negative (-2. 9 + / - 0. 5 vs. -1. 3 + / - 0. 5 ; p =. 025), and general psychopathology (-7. 0 + / - 1. 1 vs. -2. 7 + / - 1. 2 ; p =. 0061) subscales.